个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Yu, Rong[1] * ; Wang, Wenqing[2] * ; Li, Tao[3] ; Li, Jiancheng[4] ; Zhao, Kuaile[5] ; Wang, Weihu[1] ; Liang, Long[3] ; Wu, Haishan[4] ; Ai, Tashan[5] ; Huang, Wei[6] ; Li, Liyun[6] ; Yu, Wentao[6] ; Wei, Chenlu[6] ; Wang, Yidi[6] ; Shen, Wei[6] ; Xiao, Zefen[2] ;
机构： [1]Department of Radiation Oncology, Peking University Cancer Hospital, Beijing, China [2]Cancer Hospital & Institute, Chinese Academy of Medical Sciences, Beijing, China [3]Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu, China [4]Department of Radiation Oncology, Fujian Cancer Hospital, Fuzhou, China [5]Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China [6]BeiGene (Beijing) Co., Ltd., Beijing, China
出处：
DOI： 10.2217/fon-2021-0632
ISSN：

关键词： concurrent chemoradiotherapy esophageal squamous cell carcinoma immune checkpoint inhibitor immunotherapy Phase III clinical trial programmed cell death-1 (PD-1) tislelizumab

基金：
BeiGene, Ltd.
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2021]版：
大类 | 4 区 医学
小类 | 4 区 肿瘤学
最新[2023]版：
大类 | 4 区 医学
小类 | 4 区 肿瘤学
JCR分区：
出版当年[2021]版：
Q3 ONCOLOGY
最新[2023]版：
Q2 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者机构： [1]Department of Radiation Oncology, Peking University Cancer Hospital, Beijing, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Yu Rong,Wang Wenqing,Li Tao,et al.RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma[J].FUTURE ONCOLOGY.2021,17(31):4081-4089.doi:10.2217/fon-2021-0632.
APA：
Yu, Rong,Wang, Wenqing,Li, Tao,Li, Jiancheng,Zhao, Kuaile...&Xiao, Zefen.(2021).RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma.FUTURE ONCOLOGY,17,(31)
MLA：
Yu, Rong,et al."RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma".FUTURE ONCOLOGY 17..31(2021):4081-4089

相关文献

[1]GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy [2]Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients [3]A phase III multicenter randomized clinical trial of 60 Gy vs 50 Gy radiation dose in concurrent chemoradiotherapy for inoperable esophageal squamous cell carcinoma. [4]Concurrent chemoradiotherapyof different radiation doses and different irradiation fields for locally advanced thoracic esophageal squamous cell carcinoma: A randomized, multicenter, phase III clinical trial [5]Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: A multicenter, randomized, parallel-controlled, phase II clinical trial [6]Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) [7]Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension [8]Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) [9]Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) [10]CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis.

资源点击量：52808 今日访问量：2 总访问量：4561 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号